BCG vaccine immunity against human tuberculosis. The BCG vaccine can be anywhere from 0 to 80% effective in preventing tuberculosis for a duration of 15 years; however, its protective effect appears to vary according to geography and the lab in which the vaccine strain was grown. A number of different companies make BCG, sometimes using different genetic strains of the bacterium. This may result in different product characteristics. OncoTICE, used for bladder instillation for bladder cancer, was developed by Organon Laboratories (since acquired by Schering-Plough, and in turn acquired by Merck & Co.). Pacis BCG, made from the Montréal (Institut Armand-Frappier) strain,
Belarusian Railway BCG-1 24, 2012. Belarusian Railway BCG-1 The Belarusian Railways BCG-1, originally Belarusian Railways BKG-1 (БКГ : "Белорусско-Китайский Грузовой"), is a type of twin-unit, eight axle, (Bo'Bo')-(Bo'Bo'), high power mainline electric freight locomotive manufactured by CNR Datong Electric Locomotive for the Belarusian Railway. The locomotives are derived from the China Railways HXD2 locomotive type developed from the Alstom Prima locomotive platform. In April 2010 CNR Datong announced that it had obtained a 700million Yuan contract to supply 12 twin section electric locomotives to Belarus; the locomotives were to be used to increase haulage capacity from the 4700t to 5500t capacity of the